Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival | Aplastic Anemia and MDS International Foundation

Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival

Journal Title: 
Am J Clin Pathol
Author(s): 
Johnson RC, Kurzer JH, Greenberg PL, Gratzinger D
Primary Author: 
Johnson RC
Original Publication Date: 
Monday, December 1, 2014

OBJECTIVES:

We retrospectively tested the prognostic and diagnostic significance of CD271+ mesenchymal stromal cell (MSC) density in cytopenic patients who underwent bone marrow biopsy to evaluate for myelodysplastic syndromes (MDS).

METHODS:

CD271+ MSC density was quantitated by automated image analysis of tissue microarray cores in 125 cytopenic patients: 40 lower grade MDS (<5% marrow blasts), 24 higher grade MDS, and 61 benign.

RESULTS:

CD271+ MSC density was increased in higher grade MDS compared with benign (P = .006) and lower grade MDS (P = .02). CD271+ MSC density was predictive of survival among patients with MDS independent of Revised International Prognostic Scoring System (IPSS-R), history of transfusion, therapy-related MDS, and fibrosis (hazard ratio, 3.4; P < .001). Among low or intermediate IPSS-R patients, median survival was significantly shorter in the high CD271+ MSC density group (47 vs 18 months, P < .02).

CONCLUSIONS:

High CD271+ MSC density is characteristic of higher grade MDS and is associated with poor risk independent of known prognostic factors.

Bone Marrow Diseases: